We are live on ! Find out more
ANAC

ANACOR PHARMACEUTICALS INC COM
ANAC

Delisted

ANAC was delisted on the 23rd of June, 2016.

107 hedge funds and large institutions have $596M invested in ANACOR PHARMACEUTICALS INC COM in 2014 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 47 increasing their positions, 31 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

87% more call options, than puts

Call options by funds: $2.08M | Put options by funds: $1.12M

52% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 31

19% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 16

2% more funds holding

Funds holding: 105107 (+2)

9% less capital invested

Capital invested by funds: $653M → $596M (-$56.2M)

25% less funds holding in top 10

Funds holding in top 10: 43 (-1)

Holders
107
Holders Change
+2
Holders Change %
+1.9%
% of All Funds
3.08%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.09%
New
19
Increased
47
Reduced
31
Closed
16
Calls
$2.08M
Puts
$1.12M
Net Calls
+$967K
Net Calls Change
+$821K
Name Holding Trade Value Shares
Change
Change in
Stake
D.E. Shaw & Co
76
D.E. Shaw & Co
New York
$358K +$90.8K +5,641 +39%
Group One Trading
77
Group One Trading
Illinois
$353K +$106K +6,613 +50%
CA
78
Corrado Advisors
New Jersey
$352K -$138K -8,600 -30%
BA
79
BlackRock Advisors
Delaware
$352K +$11.3K +705 +4%
PNC Financial Services Group
80
PNC Financial Services Group
Pennsylvania
$304K +$75K +4,659 +37%
BNP Paribas Financial Markets
81
BNP Paribas Financial Markets
France
$287K +$67.7K +4,208 +35%
Bank of America
82
Bank of America
North Carolina
$265K +$116K +7,191 +93%
SO
83
STRS Ohio
Ohio
$257K +$33.8K +2,100 +17%
RNS
84
Robert N. Shapiro
$242K -$966 -60 -0.4%
Susquehanna International Group
85
Susquehanna International Group
Pennsylvania
$237K -$310K -19,236 -59%
GCP
86
GSA Capital Partners
United Kingdom
$212K +$193K +11,976 New
Principal Financial Group
87
Principal Financial Group
Iowa
$192K -$30.8K -1,915 -15%
Jane Street
88
Jane Street
New York
$188K +$171K +10,611 New
DIA
89
Denver Investment Advisors
Colorado
$187K +$170K +10,553 New
WS
90
Wedbush Securities
California
$184K +$167K +10,400 New
Barclays
91
Barclays
United Kingdom
$150K -$193K -11,992 -58%
MCM
92
Manchester Capital Management
Vermont
$134K
FANJ
93
Financial Architects (New Jersey)
New Jersey
$106K +$96.6K +6,000 New
Bank of Montreal
94
Bank of Montreal
Ontario, Canada
$65K +$10.3K +640 +21%
VFA
95
Virtus Fund Advisers
Connecticut
$50K +$45.2K +2,810 New
LTFS
96
Ladenburg Thalmann Financial Services
Florida
$49K
Citigroup
97
Citigroup
New York
$43K -$75.4K -4,686 -66%
GXMC
98
Global X Management Company
New York
$26K +$24K +1,493 New
BG
99
BlackRock Group
United Kingdom
$25K +$22.7K +1,409 New
Teacher Retirement System of Texas
100
Teacher Retirement System of Texas
Texas
$22K +$19.5K +1,214 New

ANAC Hedge Fund Activity: Q2 2014 in Review

107 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in ANACOR PHARMACEUTICALS INC COM (ANAC) for Q2 2014, worth a combined $596M — down 8.6% from $653M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new ANAC positions and 16 closed out — a net gain of 3 holders — while 47 added to existing stakes and 31 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $10.2M. The largest seller was Consonance Capital Management, cutting an estimated $11.6M.

  • 107 institutional investors held ANACOR PHARMACEUTICALS INC COM (ANAC) as of Q2 2014, up from 105 in Q1 2014.
  • Funds reported $596M of ANACOR PHARMACEUTICALS INC COM stock for Q2 2014, down 8.6% quarter-over-quarter.
  • 19 funds opened new ANACOR PHARMACEUTICALS INC COM positions in Q2 2014 and 16 closed out, a net change of +3 holders.
  • The largest ANACOR PHARMACEUTICALS INC COM buyer in Q2 2014 was Fidelity Investments, an estimated $10.2M added.
  • The largest ANACOR PHARMACEUTICALS INC COM seller in Q2 2014 was Consonance Capital Management, an estimated $11.6M sold.

Based on aggregated 13F filings for Q2 2014.